Daily close, T-120 (10/11/24) through T+5. Run-up high $59.42 on 3/6/25, low $45.89 on 12/23/24 (T-120 to T-1). FDA decision 3/28/25. Historical price action, not a forecast.
Positioning before the decision
On Mar 14, 2025, 14 days before the decision date, at-the-money options priced a move of ±5.2% through Apr 17, 2025 (the first listed expiry after the decision; ATM implied volatility 21%). The stock closed +1.7% at the first close across the decision and -0.5% five trading days on. A straddle priced weeks out covers ordinary movement plus the event, so this is the move the options market priced through that expiry, not the event-implied move alone. How this compares across 1,000+ decisions.
Was Qfitlia (fitusiran) - (ATLAS) approved by the FDA?
Yes. The FDA approved the application for Qfitlia (fitusiran) - (ATLAS) on March 28, 2025. The primary source is linked on this page.
What was Qfitlia (fitusiran) - (ATLAS) under FDA review for?
The application covered Hemophilia A/B. The FDA approved the application on March 28, 2025.
How did SNY stock react to the FDA decision?
On the decision day SNY moved +1.7%. That is the recorded reaction to this specific event -- historical measurement, not a prediction, and not investment advice.